266 related articles for article (PubMed ID: 38318177)
1. EBF1, PAX5, and MYC: regulation on B cell development and association with hematologic neoplasms.
Li L; Zhang D; Cao X
Front Immunol; 2024; 15():1320689. PubMed ID: 38318177
[TBL] [Abstract][Full Text] [Related]
2. EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene.
Somasundaram R; Jensen CT; Tingvall-Gustafsson J; Åhsberg J; Okuyama K; Prasad M; Hagman JR; Wang X; Soneji S; Strid T; Ungerbäck J; Sigvardsson M
Blood; 2021 Jun; 137(22):3037-3049. PubMed ID: 33619557
[TBL] [Abstract][Full Text] [Related]
3. EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism.
Ramamoorthy S; Kometani K; Herman JS; Bayer M; Boller S; Edwards-Hicks J; Ramachandran H; Li R; Klein-Geltink R; Pearce EL; Grün D; Grosschedl R
Genes Dev; 2020 Nov; 34(21-22):1503-1519. PubMed ID: 33004416
[No Abstract] [Full Text] [Related]
4. EBF1 drives hallmark B cell gene expression by enabling the interaction of PAX5 with the MLL H3K4 methyltransferase complex.
Bullerwell CE; Robichaud PP; Deprez PML; Joy AP; Wajnberg G; D'Souza D; Chacko S; Fournier S; Crapoulet N; Barnett DA; Lewis SM; Ouellette RJ
Sci Rep; 2021 Jan; 11(1):1537. PubMed ID: 33452395
[TBL] [Abstract][Full Text] [Related]
5. Aryl Hydrocarbon Receptor Activation Suppresses EBF1 and PAX5 and Impairs Human B Lymphopoiesis.
Li J; Bhattacharya S; Zhou J; Phadnis-Moghe AS; Crawford RB; Kaminski NE
J Immunol; 2017 Nov; 199(10):3504-3515. PubMed ID: 28978690
[TBL] [Abstract][Full Text] [Related]
6. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia.
Heltemes-Harris LM; Willette MJ; Ramsey LB; Qiu YH; Neeley ES; Zhang N; Thomas DA; Koeuth T; Baechler EC; Kornblau SM; Farrar MA
J Exp Med; 2011 Jun; 208(6):1135-49. PubMed ID: 21606506
[TBL] [Abstract][Full Text] [Related]
7. Early B-cell factor 1 regulates the expansion of B-cell progenitors in a dose-dependent manner.
Åhsberg J; Ungerbäck J; Strid T; Welinder E; Stjernberg J; Larsson M; Qian H; Sigvardsson M
J Biol Chem; 2013 Nov; 288(46):33449-61. PubMed ID: 24078629
[TBL] [Abstract][Full Text] [Related]
8. B Lymphocyte commitment program is driven by the proto-oncogene c-Myc.
Vallespinós M; Fernández D; Rodríguez L; Alvaro-Blanco J; Baena E; Ortiz M; Dukovska D; Martínez D; Rojas A; Campanero MR; Moreno de Alborán I
J Immunol; 2011 Jun; 186(12):6726-36. PubMed ID: 21572027
[TBL] [Abstract][Full Text] [Related]
9. Combined heterozygous loss of Ebf1 and Pax5 allows for T-lineage conversion of B cell progenitors.
Ungerbäck J; Åhsberg J; Strid T; Somasundaram R; Sigvardsson M
J Exp Med; 2015 Jun; 212(7):1109-23. PubMed ID: 26056231
[TBL] [Abstract][Full Text] [Related]
10. EBF1-JAK2 inhibits the PAX5 function through physical interaction with PAX5 and kinase activity.
Kojima Y; Kawashima F; Yasuda T; Odaira K; Inagaki Y; Yamada C; Muraki A; Noura M; Okamoto S; Tamura S; Iwamoto E; Sanada M; Matsumura I; Miyazaki Y; Kojima T; Kiyoi H; Tsuzuki S; Hayakawa F
Int J Hematol; 2023 Jul; 118(1):65-74. PubMed ID: 37149540
[TBL] [Abstract][Full Text] [Related]
11. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.
Chung EY; Psathas JN; Yu D; Li Y; Weiss MJ; Thomas-Tikhonenko A
J Clin Invest; 2012 Jun; 122(6):2257-66. PubMed ID: 22546857
[TBL] [Abstract][Full Text] [Related]
12. Transcription factor Pax5 (BSAP) transactivates the RAG-mediated V(H)-to-DJ(H) rearrangement of immunoglobulin genes.
Zhang Z; Espinoza CR; Yu Z; Stephan R; He T; Williams GS; Burrows PD; Hagman J; Feeney AJ; Cooper MD
Nat Immunol; 2006 Jun; 7(6):616-24. PubMed ID: 16680144
[TBL] [Abstract][Full Text] [Related]
13. Runx1-Cbfβ facilitates early B lymphocyte development by regulating expression of Ebf1.
Seo W; Ikawa T; Kawamoto H; Taniuchi I
J Exp Med; 2012 Jul; 209(7):1255-62. PubMed ID: 22665574
[TBL] [Abstract][Full Text] [Related]
14. Ebf1 and c-Myb repress rag transcription downstream of Stat5 during early B cell development.
Timblin GA; Schlissel MS
J Immunol; 2013 Nov; 191(9):4676-87. PubMed ID: 24068669
[TBL] [Abstract][Full Text] [Related]
15. Distinct promoters mediate the regulation of Ebf1 gene expression by interleukin-7 and Pax5.
Roessler S; Györy I; Imhof S; Spivakov M; Williams RR; Busslinger M; Fisher AG; Grosschedl R
Mol Cell Biol; 2007 Jan; 27(2):579-94. PubMed ID: 17101802
[TBL] [Abstract][Full Text] [Related]
16. Pax5--a critical inhibitor of plasma cell fate.
Nera KP; Lassila O
Scand J Immunol; 2006 Sep; 64(3):190-9. PubMed ID: 16918686
[TBL] [Abstract][Full Text] [Related]
17. A dose-dependent role for EBF1 in repressing non-B-cell-specific genes.
Lukin K; Fields S; Guerrettaz L; Straign D; Rodriguez V; Zandi S; Månsson R; Cambier JC; Sigvardsson M; Hagman J
Eur J Immunol; 2011 Jun; 41(6):1787-93. PubMed ID: 21469119
[TBL] [Abstract][Full Text] [Related]
18. PDK1 regulates VDJ recombination, cell-cycle exit and survival during B-cell development.
Venigalla RK; McGuire VA; Clarke R; Patterson-Kane JC; Najafov A; Toth R; McCarthy PC; Simeons F; Stojanovski L; Arthur JS
EMBO J; 2013 Apr; 32(7):1008-22. PubMed ID: 23463102
[TBL] [Abstract][Full Text] [Related]
19. Pax5: a master regulator of B cell development and leukemogenesis.
Medvedovic J; Ebert A; Tagoh H; Busslinger M
Adv Immunol; 2011; 111():179-206. PubMed ID: 21970955
[TBL] [Abstract][Full Text] [Related]
20. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells.
Beer S; Wange LE; Zhang X; Kuklik-Roos C; Enard W; Hammerschmidt W; Scialdone A; Kempkes B
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2200512119. PubMed ID: 35857872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
